• Brand Name: Rozlytrek
  • Innovator Brand Name: Rozlytrek
  • API: Entrectinib
  • Packaging: 30/90 Capsules
  • Strength: 100/200mg
  • Manufacturer Name: Genentech
Get Price


Entrectinib Uses

Entrectinib is a kinase inhibitor used for the Treatment of:

  • ROS1-Positive Non-Small Cell Lung Cancer
  • NTRK Gene Fusion-Positive Solid Tumors

Dosage: The recommended entrectinib Capsule dose for patients with ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors is 600 mg orally once daily with or without food until the disease is progressive or unacceptable toxicity is noticed. Swallow the entrectinib capsules whole. Do not open, crush, chew, or dissolve the contents of the capsule. In case of missed dose, patients are instructed to make up that dose unless the next dose is due within 12 hours. If vomiting occurs promptly after taking a dose, patients are instructed to repeat that dose.

Side Effects: The most commonly reported entrectinib Capsule side effects include:

  • Fatigue
  • Constipation
  • Dysgeusia
  • Edema
  • Dizziness
  • Diarrhea
  • Nausea
  • Dysesthesia
  • Dyspnea
  • Myalgia
  • Cognitive impairment
  • Increased weight
  • Cough
  • Vomiting
  • Pyrexia
  • Arthralgia
  • Vision disorders

Warnings and Precautions:

  • Patients should be assessed for left ventricular ejection fraction (LVEF) before initiation of Rozlytrek with symptoms or known risk factors for CHF.
  • Patients with entrectinib should be monitored for liver tests, including ALT and AST, every 14 days during the first month of therapy, then monthly thereafter.
  • Patients should be assessed for serum uric acid levels prior to starting therapy with Rozlytrek capsules and periodically while on treatment.
  • Patients with Rozlytrek Capsule treatment should be monitored for signs and symptoms of hyperuricemia. Use of entrectinib may cause fetal harm if administered to a pregnant woman.
  • Females are advised not to breastfeed during treatment with rozlytrek capsules and for one week after the final dose.

More info

Storage: Store Rozlytrek (Entrectinib) at room temperature (15-30°C). This medicine should not be used following the expiry date shown on the pack. Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the ROZLYTREK at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the ROZLYTREK Capsules. Buying Procedure: In order to buy ROZLYTREK, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: info@theindianpharma.com along with the legitimate ID Proof, standard Prescription and Medical Reports. Conclusion: In conclusion, therapy with entrectinib capsules expands the range of treatment options for advanced NTRK +Ve solid tumours and ROS1 +Ve NSCLC, and may be of particular value in patients with existing CNS metastases and those who are at risk of developing CNS metastases.


What is Rozlytrek? Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. What does Rozlytrek contain as an active substance? The medication Rozlytrek specifically contains the active substance Entrectinib. How is Entrectinib supplied? Entrectinib is supplied as Capsules, 100 mg and 200 mg for oral administration. What should I avoid while taking Rozlytrek?
  • Drinking grapefruit juice
  • Eating grapefruit
  • Driving or operating heavy machinery
How much does rozlytrek cost? The rozlytrek price in India usually may vary depending on the wholesaler/pharmacy you visit and of course the brand you choose. What is the best price for Entrectinib? Please contact Toll-free: +91 1800 889 1064|+919310090915 for entrectinib price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements. Can I get Rozlytrek (Entrectinib) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Rozlytrek (Entrectinib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.